Quality of life
Introduction
Quality of life (QoL) and costs of medical and social care represent, in addition to mortality, the fundamental criteria n been steadily growing [1, 2] . In addition to the increasing direct medical costs spent on treatment of AF and its complications, expenses on working incapacity, lost profits, invalidity, and social benefits also need to be taken into consideration. This study sought to evaluate quality of life and socioeconomic parameters in patients undergoing AF ablation. It further assessed costs of conventional therapy one year before ablation and two years after ablation.
Methods

Patients
The study included 160 consecutive patients aged Z18 years who underwent their first catheter ablation for symptomatic AF in the year 2007 in two centers, and who were subsequently prospectively followed-up for 2 years.
Data collection
Demographic, medical, social, and socioeconomic data obtained from the patients' history and examinations during the index hospitalization and subsequent outpatient visits were analyzed. This data was recorded into a questionnaire and stored on an internet portal under the personal patient's code.
Assessment of quality of life and socioeconomic parameters
QoL was assessed by the European Quality of Life Group instrument-EQ-5D self report questionnaire. This standardized questionnaire consists of 2 parts-EQ-VAS (visual analog scale of 0-100 for recording individuals' rating of their current health-related QoL state), and the 3-level, 5-dimensional descriptive system (EQ-5D), which evaluates mobility, self-care, usual activities, pain/discomfort and anxiety/depression on a 0-100 scale using the European value set [3] . Patients filled out the questionnaire on their own without any assistance from medical staff before, and every six months after the ablation, when the questionnaires were sent them home by post. Counts of days of hospitalization and working capacity per patient per 6 month were assessed before ablation and for each 6-month post-ablation period. All patients completed 24-month follow-up.
Assessment of costs of conventional therapy
Yearly costs of conventional therapy per patient one year before ablation and two years after ablation were evaluated. At the same time, costs of ablation therapy were ascertained. Repeat ablation was performed by the end of the follow-up period in 57 (36%) patients; 7 (4%) patients underwent two repeat ablation procedures. Thus, in total, 64 repeat ablation procedures were calculated. The count of outpatient visits was averaged for each followup period. The expenses on days spent in working incapacity were calculated from mean salary in the Czech Republic which was 22.748 Czech Crowns (CZC) (910h). The costs of hospitalizations were calculated from the daily rate applied by Czech General Health Insurance Company. Costs of drugs were obtained from their mean price, costs of laboratory and diagnostic tests were determined from the price list of the Czech General Health Insurance Company. The costs of diagnostic/therapeutic procedures were calculated from the count of procedures per 1 patient per 1 year in relation to the point rating of a particular procedure. The remaining health care costs were calculated from the current rating of the Czech General Health Insurance Company.
Statistical analysis
Data from the questionnaires was edited in the Microsoft Excel verze 9.0.2812 program. All analyses were performed using the Statistica version 6.1 software (Statsoft, Inc.). Continuous variables were expressed as mean7standard deviation and compared by the 2-tailed Student's t-test. Categorical variables were expressed as percentages and compared by w 2 -test. A p value o0.05 was considered significant.
Results
Mortality and questionnaire recoverability
During the follow up, 2 (1%) patients died 12 and 20 months after ablation, respectively. Hemorrhagic stroke was the cause of death in both patients who continued to use warfarin. 
Questionnaire was recovered from 125 (78%), 110 (69%), 136 (85%), and 122 (76%) patients after 6, 12, 18 and 24 months, respectively.
Baseline characteristics
Baseline characteristics are listed in Table 1 . Palpitations, sweating, fatigue, and incapacity dominated the symptoms (Table 2) . Baseline medication is shown in Table 3 .
Ablation procedure characteristics
Procedure time (304777 min), fluoroscopy time (34731 min), and radiofrequency application time (89752 min) reflected participation of operators with different experience and inclusion of patients with persistent AF requiring more complex ablation strategy. Occurrence of 3 serious complications in 3 (2%) patients, namely cardiac tamponade in 2 (1.3%) patients, and transient ischemic attack in 1 (0.6%) patients did not differ from the results of worldwide registries [4, 5] .
Quality of life-questionnaire EQ-5D
EQ-5D index of quality of life improved already after 6 months (p ¼0.02), and the improvement persisted at all the follow-up stages (all po0.001). EQ-VAS score of quality of life increased significantly after 12 months (p ¼0.02), and its amelioration also persisted after 18 and 24 months, respectively (po0.01, and p¼ 0.01, respectively) ( Fig. 1) .
Socioeconomic parameters
Pre-ablation count of hospitalization days/1 patient/6 months was 4.2 days, and decreased to 1.3 days 6 months after ablation (p¼ 0.01), and to 1.1, 1.0, and 0.9 days, respectively after 12, 18, and 24 months, respectively (all po0.01) (Fig. 2) . Pre-ablation count to days of working incapacity/1 patient/ 6 months amounted to 14.2, and decreased insignificantly after 6 months to 12.5 days, however, subsequently dropped significantly to 4.9 days after 12 months (p ¼0.02), and to 2.0 and 1.7 days, respectively, after 18 and 24 months (both po0.01) (Fig. 2). 
3.6.
Costs of conventional therapy
The mean cost of ablation procedures per 1 patient including repeat ablations was 259.000 CZC (10.360h). The costs of conventional therapy per 1 patient per 1 year summed up to 49.337 CZC (1.974h) before ablation, while they were reduced to 16.504 CZC (660h) in the first post-ablation year and to 13.576 CZC (543h) in the second post-ablation year (Table 4) 
Discussion
This study analyzed quality of life, socioeconomic parameters, and costs conventional therapy in patients undergoing catheter ablation for AF. The main findings of the study are as follows: (1) quality of life assessed by the questionnaire EQ-5D improved significantly in both its portions at all follow-up stages; (2) ablation was associated with significant decrease in hospitalization days and days of working incapacity; (3) more than three-fold reduction in the cost of conventional therapy was observed in the first two years after ablation.
Quality of life and socioeconomic parameters
This study corroborated prior observations of significant improvement of QoL in patients after catheter ablation of AF [6] [7] [8] [9] . Recent studies similarly to our study demonstrated that the improvement of quality of life persisted long term [10, 11] . In addition, the counts of days of hospitalization and working incapacity were significantly reduced. The greatest benefit was achieved after one year and later when AF/ atrial tachycardia recurrences disappeared either spontaneously (in case of early temporary arrhythmia), or after successful repeat ablation. Specifically, decrease in days of working incapacity was only insignificant after 6 months, while a 7-8 fold reduction was observed after 18 and 24 months.
Cost of conventional therapy
Earlier analysis in patients with AF treated by private internists/cardiologists in the Czech Republic and not undergoing catheter ablation demonstrated 1-year costs of conventional AF therapy per 1 patient to amount to 42.407 CZC (1.697h) [12] . The Czech costs of conventional AF therapy were approximately half the common costs in western European countries possibly as a result of lower labor costs [13, 14] . In this study, expenses on AF treatment in patients undergoing catheter ablation were assessed, and by reaching 49.337 CZC (1.974h)
per patient per year exceeded the expenses found in the above mentioned population [12] by nearly 7.000 CZC (280h). It can be speculated that patients undergoing ablation are likely to be more symptomatic and require more pharmacologic and other interventions. Considering the costs of all ablation procedures per 1 patient of 259.000 CZC (10.360h), and considering the costs of continuing conventional therapy of 16.504 CZC (660h) in the first post-ablation year and 13.576 CZC (543h) in the second post-ablation year, respectively, and estimating similar costs of conventional therapy during the following years, the costs of ablation therapy should be paid back within 7-8 years. This simple arithmetic calculation, however, does not reflect more complex health and social care issues. First, progression of complications of AF and use of more expensive drugs may escalate the costs of conventional therapy in patients who do not undergo timely ablation. Arrhythmia-induced cardiomyopathy, which is reversible after successful ablation [15, 16] , often kindles a chain of wrong diagnostic and curative steps (repeat negative coronary angiographies, primary preventive ICD implantation, etc.) without hope in cure, however, with immense subsequent expenses on compromise therapeutic strategies (heart failure therapy, ICD reimplantations, etc). Medical treatment with angiotensin-converting enzyme Fig. 1 -Panels A and B show evolution of EQ-5D index and EQ-VAS score of quality of life on a 0-100 scale before ablation and at the 6, 12, 18, and 24 month post-ablation stages as assessed by EQ-5D questionnaire. Improvements in both portions became significant after 6 months and remained significant after 2 years (p-values in the text). On the other hand, the first two years after ablation represent a period of possible repeat ablation procedures and relatively intensive outpatient care, while full clinical and economic benefit is achieved only later. Therefore, it is possible that the costs of continuing conventional therapy in the subsequent post-ablation years are lower, and AF ablation becomes cost-effective earlier.
Finally, this study did not calculate savings resulting from recovered health and working capacity, or, on the contrary, expenditures on further disease progression, continuing working incapacity and invalidity. Importantly, AF ablation immensely impacts an otherwise healthy population of an average age of 55-60 years. With regard to this issue, this study group included 8% of invalid patients in whom AF itself was the dominant cause of invalidity. AF ablation, in stark contrast to other expensive cardiology disciplines, treats mainly active and productive patients, in whom the expenses on ablation will often be paid back still in their productive age. Absolute values of quality of life indicate that these patients return into the state of full health and productivity. Therefore the global economic profit from successful ablation is possibly achieved much earlier than can be calculated from direct costs of medical care. More reliable calculation of costefficacy in relation to social expenditures would, however, need more complex mathematical models [17] .
Limitations
Because the follow-up questionnaires were mailed to the patients home, and because the patients responded voluntarily, the data evaluation was limited only to the responders. However, the questionnaire recovery between 66% and 84% at different stages of the study was favorable when compared with similar questionnaire projects. Furthermore, this study practice ensured independence of the responding patients who were not influenced of even biased by the medical staff assistance.
Conclusions
Catheter ablation of AF significantly improved QoL and reduced hospital admissions and working incapacity at all stages of the 2-year follow-up. In addition, more than three-fold reduction in the costs of conventional therapy was achieved in the first two years after ablation.
